News ( Year: 2017 )

SORT BY YEAR
28 August, 2017

Synlogic Completes Merger with Mirna Therapeutics

CAMBRIDGE, Mass. & AUSTIN, Texas–(BUSINESS WIRE)–Aug. 28, 2017– Synlogic, Inc. and Mirna Therapeutics, Inc. today announced that the proposed merger of the two companies has closed following the approval of Mirna’s stockholders received on August 24, 2017. The merged company will operate as Synlogic, Inc. and will focus on advancing Synlogic’s platform for development of […]

Read More
15 June, 2017

PE-backed WuXi Biologics completes Hong Kong re-listing

WuXi Biologics, a Chinese contract R&D services provider to the global pharmaceutical industry that was taken private by a PE-backed consortium in late 2015, gained 38% on its Hong Kong trading debut following a HK$3.97 billion ($510 million) IPO. The company sold 192.9 million shares at HK$20.60 apiece, according to a filing, although the size […]

Read More
25 May, 2017

Ally Bridge reaches ‘inflection point’ with Wuxi IPOs – Profiler

Ally Bridge, the healthcare investment group that whisked Shanghai-based Wuxi Pharmatech from under the noses of established global private equity firms in 2015, is “reaching an inflection point”, according to founder Frank Yu. Established five years ago Ally Bridge has matured into a larger healthcare growth capital and buyout firm via its Flagship fund, while […]

Read More
24 May, 2017

Wuxi Biologics, Wuxi Apptech’s IPOs could benefit from scarcity value – Ally Bridge founder Frank Yu

 Wuxi Biologics has ‘scarcity value’, worth 10% to 15% of group  Future HK IPO of Shandong Luoxin is possible The listings of Wuxi Biologics in Hong Kong and the remainder of WuxiPharmatech‘s assets in China will benefit from their scarcity value, according to Frank Yu, founder of Ally Bridge, the firm that led the delisting the Shanghai-based Wuxi Pharmatech from New York in 2015. Wuxi Biologics, which was incorporated in […]

Read More
16 March, 2017

Aerpio Pharmaceuticals Raises $40 Million

Aerpio Pharmaceuticals, Inc. (the “Company”), a biopharmaceuticalcompany focused on advancing first-in-class treatments for ocular diseases, today announced thesuccessful completion of its reverse merger transaction with Aerpio Therapeutics, Inc. (“Aerpio”) and Aerpio Acquisition Corp. (“Merger Sub”), a wholly-owned subsidiary of the Company. Following the reverse merger transaction, the Company will continue the historical business of Aerpio. […]

Read More
21 February, 2017

Ally Bridge Group Expands European Life Science Portfolio with New Investments and Establishes Presence in Europe

HONG KONG and ZUG, Switzerland, Feb. 21, 2017 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading global cross-border healthcare investment group, announced that in recent months it has completed investments in two European biopharmaceutical companies — Galenica AG (SIX: GALN) of Switzerland, and Nabriva (NASDAQ: NBRV) of Austria and the US. These two companies, both […]

Read More